secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-063975
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics Q1 net loss $51.7M; on track for Phase 3 atacicept results in 2Q 2025
--------------------------------------------------------------------------------

- Net loss of $51.7M ($0.81/share) vs $28.4M ($0.56/share) same quarter last year.
- Cash, equivalents and marketable securities of $589.8M as of March 31, 2025.
- Primary endpoint results from atacicept pivotal Phase 3 ORIGIN trial in IgAN expected in 2Q 2025.
- BLA submission for atacicept accelerated approval planned for 4Q 2025; potential launch in 2026.
- Expanded atacicept program into primary membranous nephropathy, FSGS, and minimal change disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000095017025063975/0000950170-25-063975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000095017025063975/vera-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer